Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CRN09682 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Multiple Dose Levels administered Q3W |
| Dose Expansion: Cohort 1 | EXPERIMENTAL | Pancreatic Neuroendocrine Tumor (NET) |
| Dose Expansion: Cohort 2 | EXPERIMENTAL | Non-Pancreatic NET |
| Dose Expansion: Cohort 3 | EXPERIMENTAL | Neuroendocrine Carcinoma (NEC) |
| Dose Expansion: Cohort 4 | EXPERIMENTAL | Other Solid Tumors |
| Name | Type | Description |
|---|---|---|
| CRN09682 | DRUG | Study drug CRN09682 intravenously |
Inclusion Criteria: * Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression. * Have one or more measurable disease location per RECIST version 1.1. * Have a tumor that expresses SSR confirmed by SSR im...
CRN09682 is an investigational small molecule being developed for the treatment of SST2-positive neuroendocrine neoplasms (NENs), including neuroendocrine tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CRN09682 targets the somatostatin receptor subtype 2 (SST2). This receptor is expressed on certain neuroendocrine neoplasms, and the drug is designed to interact with it as part of its therapeutic mechanism.
CRN09682 is being developed by Crinetics Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CRNX. The company is conducting clinical trials to evaluate the drug's safety and effectiveness.
CRN09682 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is actively recruiting participants.
CRN09682 is being studied in a Phase 1 clinical trial with the identifier NCT07129252. This trial is investigating the safety and effectiveness of CRN09682 in participants with SST2-expressing neuroendocrine neoplasms and other solid tumors. The trial is recruiting up to 150 participants in the United States and Spain.
CRN09682 is the sole name provided for this investigational drug. No alternative names or aliases have been reported for this compound in the available information.